Therapeutics like the remdesivir, hydroxychloroquine, lopinavir/ritonavir, and interferon regimens which healthcare systems around the world were swearing on in the absence of a vaccine, turned out largely ineffective, WHO says.
In what is being called as the largest COVID-19 therapeutics trial was undertaken by WHO found the abovestated regimes which were largely used to treat COVID-19 patients has actually had little to no effect.
The report on the study, span on thirty-over countries has conclusive evidences that these treatments are ineffective or have little effect on overall mortality, initiation of ventilation and duration of hospital stay in hospitalized patients.
Solidarity Therapeutics is considering evaluating other treatments, to continue the search for effective COVID-19 treatments.
About 500 hospitals worldwide have been opened as trial sites for evaluating newer treatment options as an initiative by Solidarity Trial.
Evaluation of more upcoming antiviral drugs, immunomodulators, anti-SARS COV-2 monoclonal antibodies is now being considered as more satisfying therapeutic options.
The novel coronavirus has so far 1,1 million-plus lives and has infected over 39 million people globally. The US has the most number of cases, followed by India at 8.1 million and 7.4 million cases respectively, Johns Hopkins University data shows.
However, a previous report from the US study on Remdesivir — drug, originally made to tread Ebola — by Gilead showed the drug was able to cut recovery time in COVID-19 patients by 5 days, as compared to the placebo, in a trial comprising 1,062 patients.
“We are concerned the data from this open-label global trial has not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design,” the company told Reuters news agency, abut WHO’s Solidarity Trial.